UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Plasma ApoE elevations are associated with NAFLD: The PREVEND Study

PloS one, 2019-08, Vol.14 (8), p.e0220659-e0220659

2019

Volltextzugriff (PDF)

Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein

PloS one, 2012-06, Vol.7 (6), p.e39110-e39110

2012

Volltextzugriff (PDF)

Compositional Features of HDL Particles Interact with Albuminuria to Modulate Cardiovascular Disease Risk

International journal of molecular sciences, 2019-02, Vol.20 (4), p.977

2019

Volltextzugriff (PDF)

Inflammation reduces HDL protection against primary cardiac risk

European journal of clinical investigation, 2010-06, Vol.40 (6), p.483-489

2010

Volltextzugriff (PDF)

Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels

PloS one, 2013-07, Vol.8 (7), p.e68920-e68920

2013

Volltextzugriff (PDF)

High Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Recurrent Coronary Events in Postinfarction Patients

Clinical chemistry (Baltimore, Md.), 2006-07, Vol.52 (7), p.1331-1338

2006

Volltextzugriff (PDF)

Apolipoprotein E levels and apolipoprotein E genotypes in incident cardiovascular disease risk in subjects of the Prevention of Renal and Vascular End-stage disease study

Journal of clinical lipidology, 2016-07, Vol.10 (4), p.842-850

2016

Volltextzugriff (PDF)

Chronic Kidney Disease Prevalence and Rate of Diagnosis

The American journal of medicine, 2007-11, Vol.120 (11), p.981-986

2007

Volltextzugriff (PDF)

Data in support of a central role of plasminogen activator inhibitor-2 polymorphism in recurrent cardiovascular disease risk in the setting of high HDL cholesterol and C-reactive protein using Bayesian network modeling

Data in brief, 2016-09, Vol.8, p.98-104

2016

Volltextzugriff (PDF)

Influences on plasminogen activator inhibitor-2 polymorphism-associated recurrent cardiovascular disease risk in patients with high HDL cholesterol and inflammation

Atherosclerosis, 2016-07, Vol.250, p.1-8

2016

Volltextzugriff (PDF)

Plasminogen activator inhibitor-1 polymorphism (4G/5G) predicts recurrence in nonhyperlipidemic postinfarction patients

Arteriosclerosis, thrombosis, and vascular biology, 2008-03, Vol.28 (3), p.548-554

2008

Volltextzugriff (PDF)

Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in ε2ε2 subjects

Clinical biochemistry, 2018-02, Vol.52, p.67-72

2018

Volltextzugriff (PDF)

Reactive Oxygen Species, SUMOylation, and Endothelial Inflammation

International journal of inflammation, 2012-01, Vol.2012 (2012), p.1-13

2012

Volltextzugriff (PDF)

Insulin resistance involvement in prevalence of familial dysbetalipoproteinemia in ε2ε2 subjects by Bayesian network modeling

Clinical biochemistry, 2018-09, Vol.59, p.31-36

2018

Volltextzugriff (PDF)

PLA2G7 Genotype, Lipoprotein-Associated Phospholipase A2 Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European Ancestry

Circulation (New York, N.Y.), 2010-06, Vol.121 (21), p.2284-2293

2010

Volltextzugriff (PDF)

Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels

Arteriosclerosis, thrombosis, and vascular biology, 2010-08, Vol.30 (8), p.1657-1664

2010

Volltextzugriff (PDF)

Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production

American journal of physiology: endocrinology and metabolism, 2000-11, Vol.279 (5), p.E1003-E1011

2000

Volltextzugriff (PDF)

Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants

Journal of the American Society of Nephrology, 2014-12, Vol.25 (12), p.2906-2915

2014

Volltextzugriff (PDF)

Low Serum Paraoxonase-1 Activity Associates with Incident Cardiovascular Disease Risk in Subjects with Concurrently High Levels of High-Density Lipoprotein Cholesterol and C-Reactive Protein

Journal of clinical medicine, 2019-09, Vol.8 (9), p.1357

2019

Volltextzugriff (PDF)

High-density lipoproteins: taking the good with the bad

Current opinion in lipidology, 2014-06, Vol.25 (3), p.230-232

2014

Volltextzugriff (PDF)

Thrombospondin-4 polymorphism (A387P) predicts cardiovascular risk in postinfarction patients with high HDL cholesterol and C-reactive protein levels

Thrombosis and haemostasis, 2011-12, Vol.106 (6), p.1170-1178

2011

Volltextzugriff (PDF)

Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein

Metabolism, clinical and experimental, 2012-07, Vol.61 (7), p.996-1002

2012

Volltextzugriff (PDF)

An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients

Vox sanguinis, 2011-07, Vol.101 (1), p.55-60

2011

Volltextzugriff (PDF)

LPL polymorphism (D9N) predicts cardiovascular disease risk directly and through interaction with CETP polymorphism (TaqIB) in women with high HDL cholesterol and CRP

Atherosclerosis, 2011-02, Vol.214 (2), p.373-376

2011

Volltextzugriff (PDF)

NAD(P)H oxidase polymorphism (C242T) and high HDL cholesterol associate with recurrent coronary events in postinfarction patients

Atherosclerosis, 2008-01, Vol.196 (1), p.461-468

2008

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(62)

Publikationsform

Artikel
(67)
Bücher
(1)

Sprache

Englisch
(68)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Plasma ApoE elevations are associated with NAFLD: The PREVEND Study

Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein

Compositional Features of HDL Particles Interact with Albuminuria to Modulate Cardiovascular Disease Risk

Inflammation reduces HDL protection against primary cardiac risk

Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels

High Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Recurrent Coronary Events in Postinfarction Patients

Apolipoprotein E levels and apolipoprotein E genotypes in incident cardiovascular disease risk in subjects of the Prevention of Renal and Vascular End-stage disease study

Chronic Kidney Disease Prevalence and Rate of Diagnosis

Data in support of a central role of plasminogen activator inhibitor-2 polymorphism in recurrent cardiovascular disease risk in the setting of high HDL cholesterol and C-reactive protein using Bayesian network modeling

Influences on plasminogen activator inhibitor-2 polymorphism-associated recurrent cardiovascular disease risk in patients with high HDL cholesterol and inflammation

Plasminogen activator inhibitor-1 polymorphism (4G/5G) predicts recurrence in nonhyperlipidemic postinfarction patients

Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in ε2ε2 subjects

Reactive Oxygen Species, SUMOylation, and Endothelial Inflammation

Insulin resistance involvement in prevalence of familial dysbetalipoproteinemia in ε2ε2 subjects by Bayesian network modeling

PLA2G7 Genotype, Lipoprotein-Associated Phospholipase A2 Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European Ancestry

Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels

Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production

Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants

Low Serum Paraoxonase-1 Activity Associates with Incident Cardiovascular Disease Risk in Subjects with Concurrently High Levels of High-Density Lipoprotein Cholesterol and C-Reactive Protein

High-density lipoproteins: taking the good with the bad

Thrombospondin-4 polymorphism (A387P) predicts cardiovascular risk in postinfarction patients with high HDL cholesterol and C-reactive protein levels

Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein

An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients

LPL polymorphism (D9N) predicts cardiovascular disease risk directly and through interaction with CETP polymorphism (TaqIB) in women with high HDL cholesterol and CRP

NAD(P)H oxidase polymorphism (C242T) and high HDL cholesterol associate with recurrent coronary events in postinfarction patients

Suchergebnisse filtern